July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Incidence of pars plana vitrectomy for complications related to proliferative diabetic retinopathy in patients previously treated with panretinal photocoagulation.
Author Affiliations & Notes
  • Ian D Kirchner
    Krieger Eye Institute, Sinai Hospital of Baltimore, Baltimore, Maryland, United States
  • John P. McLaughlin
    Krieger Eye Institute, Sinai Hospital of Baltimore, Baltimore, Maryland, United States
  • Bao Dinh
    Internal Medicine, Inova Health System, Falls Church, Virginia, United States
  • Philip Henry Scharper
    Retina Specialists of Alabama, Montgomery, Alabama, United States
  • Footnotes
    Commercial Relationships   Ian Kirchner, None; John McLaughlin, None; Bao Dinh, None; Philip Scharper, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 874. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ian D Kirchner, John P. McLaughlin, Bao Dinh, Philip Henry Scharper; Incidence of pars plana vitrectomy for complications related to proliferative diabetic retinopathy in patients previously treated with panretinal photocoagulation.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):874.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the incidence of patients requiring pars plana vitrectomy (PPV) for complications related to proliferative diabetic retinopathy (PDR) occurring within five years following treatment with panretinal photocoagulation (PRP).

Methods : A retrospective review of 176 eyes from 100 diabetic patients that had received partial or total PRP for PDR was performed. Patients treated with PRP between 7/2005 and 11/2015 at Retina Specialists of Alabama in Montgomery and followed for at least five years were included. Eyes with intraocular surgery prior to PRP or concomitant retinal disease were excluded, along with patients with a history of systemic disease that could contribute to retinal microvascular disease. Primary outcome measures include incidence of PPV and indication for surgery.

Results : 98/176 eyes (56%) underwent PPV to treat complications related to PDR within 5 years following treatment with PRP. Indications for surgery included tractional retinal detachment (41/98), non-clearing vitreous hemorrhage (34/98), symptomatic epimacular proliferation (21/98), vitreous hemorrhage with tractional retinal detachment (1/98), and vitreous hemorrhage with epimacular proliferation (1/98). The mean number of laser burns was greater in eyes ultimately requiring surgery (1948 in progressed eyes, 1639 in non-progressed eyes), however, no statistically significant difference between the two groups was found.

Conclusions : Fifty-six percent of eyes previously treated with PRP ultimately required vitrectomy within five years after laser treatment due to complications related to diabetic retinopathy, most commonly tractional retinal detachment. In addition, the response of PDR to PRP was not significantly related to cumulative number of argon laser burns. These data call into question the long-term efficacy of PRP in preventing surgical intervention due to PDR progression. Additional prospective studies investigating alternative approaches may be warranted.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×